Last reviewed · How we verify
Dotarem®-enhanced MRI
Dotarem®-enhanced MRI is a Gadolinium-based contrast agent Small molecule drug developed by Guerbet. It is currently FDA-approved for MRI enhancement of the brain, spine, and associated tissues, MRI enhancement of the body (chest, abdomen, pelvis), MRI angiography. Also known as: Gadoterate meglumine, Gadoteric acid.
Dotarem is a gadolinium-based contrast agent that enhances MRI signal by altering the magnetic properties of nearby water molecules in tissues.
Dotarem is a gadolinium-based contrast agent that enhances MRI signal by altering the magnetic properties of nearby water molecules in tissues. Used for MRI enhancement of the brain, spine, and associated tissues, MRI enhancement of the body (chest, abdomen, pelvis), MRI angiography.
At a glance
| Generic name | Dotarem®-enhanced MRI |
|---|---|
| Also known as | Gadoterate meglumine, Gadoteric acid |
| Sponsor | Guerbet |
| Drug class | Gadolinium-based contrast agent |
| Target | Water proton relaxation (T1 relaxation time) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Dotarem contains gadolinium, a paramagnetic metal ion that shortens the T1 relaxation time of water protons in tissues, causing increased signal intensity on T1-weighted MRI images. This allows better visualization and differentiation of anatomical structures and pathological lesions. The gadolinium is chelated (bound) to DTPA (diethylenetriaminepentaacetic acid) to improve safety and reduce toxicity.
Approved indications
- MRI enhancement of the brain, spine, and associated tissues
- MRI enhancement of the body (chest, abdomen, pelvis)
- MRI angiography
Common side effects
- Headache
- Nausea
- Injection site reactions
- Dizziness
- Gadolinium deposition in tissues
Key clinical trials
- Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders (NA)
- Gadolinium Retention in Human Bone Tissue in Pediatric Patients
- Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine) (EARLY_PHASE1)
- Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance (NA)
- Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors (PHASE4)
- Renal Safety Evaluation After Dotarem®-Enhanced MRI (PHASE4)
- Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dotarem®-enhanced MRI CI brief — competitive landscape report
- Dotarem®-enhanced MRI updates RSS · CI watch RSS
- Guerbet portfolio CI
Frequently asked questions about Dotarem®-enhanced MRI
What is Dotarem®-enhanced MRI?
How does Dotarem®-enhanced MRI work?
What is Dotarem®-enhanced MRI used for?
Who makes Dotarem®-enhanced MRI?
Is Dotarem®-enhanced MRI also known as anything else?
What drug class is Dotarem®-enhanced MRI in?
What development phase is Dotarem®-enhanced MRI in?
What are the side effects of Dotarem®-enhanced MRI?
What does Dotarem®-enhanced MRI target?
Related
- Drug class: All Gadolinium-based contrast agent drugs
- Target: All drugs targeting Water proton relaxation (T1 relaxation time)
- Manufacturer: Guerbet — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for MRI enhancement of the brain, spine, and associated tissues
- Indication: Drugs for MRI enhancement of the body (chest, abdomen, pelvis)
- Indication: Drugs for MRI angiography
- Also known as: Gadoterate meglumine, Gadoteric acid
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing